NEW YORK, June 23, 2016 /PRNewswire/ --
The Biotechnology industry might still be in rough waters, but
it continues to present great opportunities to investors.
Stock-Callers.com assesses the recent performances of our featured
companies for today: Intrexon Corp. (NYSE: XON), Vertex
Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc.
(NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN).
Learn more about these stocks and receive your complimentary trade
alerts at:
http://stock-callers.com/registration
To access Stock-Callers.com full PDF Research
Packages for free, please visit the links below.
============
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
XON Research
Package: http://stock-callers.com/registration/?symbol=XON
VRTX Research
Package: http://stock-callers.com/registration/?symbol=VRTX
ARNA Research
Package: http://stock-callers.com/registration/?symbol=ARNA
REGN Research
Package: http://stock-callers.com/registration/?symbol=REGN
============
Germantown, Maryland-based
Intrexon Corp.'s stock finished Wednesday's session 0.52% lower at
$24.65 with a total volume of 1.29
million shares traded. Shares of the Company, which operates in the
synthetic biology field in the U.S., are trading below their 50-day
moving average by 13.19%. The stock has a Relative Strength Index
(RSI) of 38.94.
On Wednesday, shares in Boston,
Massachusetts headquartered Vertex Pharmaceuticals Inc.
ended the session at $85.22, slightly
down 0.07%. The stock recorded a trading volume of 1.92 million
shares. The Company's shares have gained 0.95% in the last one
month and 6.33% in the previous three months. The stock is trading
1.98% below its 50-day moving average. Moreover, shares of Vertex
Pharmaceuticals, which engages in discovering, developing,
manufacturing, and commercializing medicines for serious diseases,
have an RSI of 39.15.
San Diego, California-based
biopharmaceutical Company, Arena Pharmaceuticals Inc.'s stock
ended yesterday's session 1.07% lower at $1.85 and with a total volume of 1.14 million
shares traded. The Company's shares have advanced 14.20% in the
past month and 3.35% over the previous three months. The stock is
trading 4.72% above its 50-day moving average. Additionally, shares
of Arena Pharmaceuticals, which discovers, develops, and
commercializes novel drugs that target G protein-coupled receptors
to address unmet medical needs in the U.S. and South Korea, have an RSI of 49.46.
At the close on Wednesday, shares in Tarrytown, New York headquartered
biopharmaceutical Company, Regeneron Pharmaceuticals Inc., recorded
a trading volume of 1.80 million shares, which was above their
three months average volume of 924,230 shares. The stock finished
1.96% higher at $351.92. The
Company's shares are trading below their 50-day moving average by
9.16%. Furthermore, shares of Regeneron Pharmaceuticals, which
discovers, invents, develops, manufactures, and commercializes
medicines for the treatment of serious medical conditions globally,
have an RSI of 32.50.
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored
reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and
micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
SC has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by SC. SC is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither SC nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to
Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street,
Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA